Fresenius : Kabi completes acquisition of majority stake in mAbxience

Fresenius Kabi closed the majority stake acquisition of mAbxience Holding S.L. ("mAbxience"), a leading international biopharmaceutical company. The transaction was announced in March 2022.

The acquisition significantly strengthens Fresenius Kabi's footprint in the biopharmaceuticals space by broadening the product portfolio and expanding its production network with three state-of-the-art facilities for the production of biologic drug substance. This will enable Fresenius Kabi to cover the entire biopharmaceuticals value chain in the future and create flexible, competitive capacities for the production of the expanded biosimilars portfolio. The additional production capacities are expected to generate significant cost synergies with regard to the company's own biosimilars portfolio. Furthermore, the acquisition enables further expansion in the high-growth CDMO (Contract Development and Manufacturing Organization) market for biologics.

The purchase price will be a combination of c. €495 million upfront payment and milestone payments, strictly tied to the achievement of commercial and development targets. The contractual provisions also include a put / call option scheme regarding the sellers' and future co-owners' remaining shares in mAbxience (45%).